NASDAQ$CBUS
Cibus Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4.
Calyxt reported its Q4 2022 financial results, highlighting a merger agreement with Cibus Global and advancements in customer projects. The quarter saw nominal revenue due to the wind-down of the soybean product line, but also a decrease in operating expenses due to management actions. The company's cash runway is sufficient to fund operations through the second quarter of 2023, considering interim funding from Cibus.
- Announced a definitive merger agreement with Cibus Global, expected to close in Q2 2023.
- Continued progress on customer projects, including a pilot project for a major consumer packaged goods company.
- Achieved a milestone payment for the development of its soybean-based palm oil alternative plant trait.
- Signed an agreement with Evologic Technologies to further develop and scale its Plant Cell Matrix and BioFactory technologies.
Headline financials
Revenue & EPS history
Cibus · Revenue · Quarterly
$42K
Forward guidance
Calyxt's merger with Cibus is expected to create an industry-leading company, leveraging synergies to drive innovation and shareholder value. The combined company, renamed Cibus Inc., is expected to trade on the Nasdaq Capital Market under the ticker symbol CBUS. Corporate headquarters will be located in San Diego, California, with Calyxt’s facilities in Roseville, Minnesota remaining operational.
Tailwinds
- Merger expected to create an industry-leading company.
- Synergies expected to drive innovation and shareholder value.
- Combined company expected to trade on Nasdaq Capital Market.
- Calyxt’s facilities in Roseville, Minnesota to remain operational.
- Current customer projects under development are on track.
Headwinds
- Conditions to the closing of the Transactions are not satisfied or if consummation of the Transactions is delayed
- Calyxt’s ability to realize anticipated benefits of the proposed Transactions
- Calyxt’s ability to maintain its continued listing on the Nasdaq Capital Market
- Impact of increased competition, including competition from a broader array of synthetic biology companies
- Disruptions at its key facilities, including disruptions impacting its BioFactory production system
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-1.1%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-12.5%
Avg return
30 days after
37%
13 / 35 earnings
Positive
+23.6%
Q4 2019
Best reaction
-25.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -10.3% | -15.2% | |
| Q4 2025 | -16.7% | -24.7% | -56.8% | |
| Q3 2025 | -0.8% | +1.6% | +28.8% | |
| Q2 2025 | -3.5% | -11.6% | -7.5% | |
| Q1 2025 | -7.8% | -8.1% | -29.4% | |
| Q4 2024 | -6.4% | -9.6% | -23.7% | |
| Q3 2024 | +14.5% | +15.2% | -8.9% | |
| Q2 2024 | -9.2% | +2.7% | -42.4% | |
| Q1 2024 | +2.2% | +9.5% | -37.5% | |
| Q4 2023 | -0.7% | +2.2% | +7.4% | |
| Q3 2023 | +17.0% | +5.0% | -8.8% | |
| Q2 2023 | -9.7% | -13.8% | -19.8% | |
| Q1 2023 | -3.6% | -8.3% | -15.8% | |
| Q4 2022 | +1.6% | -0.7% | -21.5% | |
| Q3 2022 | -1.4% | -7.7% | +22.5% | |
| Q2 2022 | +12.4% | +4.3% | -11.6% | |
| Q1 2022 | -17.3% | -27.4% | -60.0% | |
| Q4 2021 | -2.8% | -21.3% | -20.6% | |
| Q3 2021 | -7.4% | -9.0% | -41.9% | |
| Q2 2021 | +12.0% | +15.1% | +19.9% | |
| Q1 2021 | +4.6% | +3.3% | -17.4% | |
| Q4 2020 | -25.1% | -24.7% | -35.6% | |
| Q3 2020 | -1.4% | -4.0% | -44.3% | |
| Q2 2020 | -6.6% | +0.2% | -8.3% | |
| Q1 2020 | -15.0% | -9.4% | +27.9% | |
| Q4 2019 | +23.6% | +22.7% | -10.1% | |
| Q3 2019 | -9.7% | -10.2% | -16.3% | |
| Q2 2019 | +2.7% | -13.1% | -23.9% | |
| Q1 2019 | -3.5% | -6.7% | -9.3% | |
| Q4 2018 | +8.3% | +20.0% | +34.0% | |
| Q3 2018 | -2.9% | -4.9% | -22.1% | |
| Q2 2018 | -0.7% | -3.1% | -10.8% | |
| Q1 2018 | +1.9% | +22.1% | +28.1% | |
| Q4 2017 | +6.4% | +18.8% | +16.9% | |
| Q3 2017 | +7.8% | +8.2% | -2.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro